A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer

Anti-Cancer Drugs

Volumn 13, Issue 5, 2002, Pages 473-480

  Gauvin, Amélie ^a   Pinguet, Frédéric ^a   Culine, Stéphane ^a   Astre, Cécile ^a   Gomeni, Roberto ^a   Bressolle, Françoise ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Limited sampling strategy; Population pharmacokinetics; Vinorelbine

Indexed keywords

NAVELBINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VINBLASTINE;

AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; METASTASIS; PRIORITY JOURNAL; EPIDEMIOLOGY; METABOLIC CLEARANCE RATE; METABOLISM; NEOPLASM; PATHOLOGY; POPULATION;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BAYES THEOREM; HUMAN; METABOLIC CLEARANCE RATE; NEOPLASMS; POPULATION; SAMPLING STUDIES; VINBLASTINE; HUMANS;

EID: 0035987058     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200206000-00005     Document Type: Article

References (27)

1. Biochemical effects of Navelbine on tubulin and associated proteins
2. Pharmacokinetics of vinorelbine in patients with liver metastases
3. Clinical pharmacokinetics of vinorelbine
4. Pharmacokinetics and metabolism of Navelbine
5. Comparative pharmacokinetics of antitumor vinca alkaloids: Intravenous bolus injections of Navelbine and related alkaloids to cancer patients and rats
6. Clinical pharmacokinetics of the antitumor drug Navelbine (5′-Noranhydrovinblastine)
7. Pharmacokinetic and preliminary metabolic fate of Navelbine in humans as determined by high performance liquid chromatography
8. Pharmacokinetics of Navelbine after oral administration in cancer patients
9. Pharmacokinetics of vinorelbine in man
10. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors
11. Relative bioavailability of two oral formulations of Navelbine in cancer patients
12. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastastic breast cancer
13. Bayesian pharmacokinetic estimation of vinorelbine in non-small cell lung cancer patients
14. Phase I and pharmacologic study of intravenous vinorelbine in patients with solid tumors
15. Pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer
16. Pharmacokinetics of a new anticancer drug, Navelbine, in patients
17. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older
18. Treatment of elderly patients with nonsmall-cell lung cancer
19. Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma: A phase II study
20. High-performance liquid chromatographic determination of vinorelbine in human plasma and blood: Application to a pharmacokinetic study
21. Experimental design and efficient parameter estimation in population pharmacokinetics
22. Design of experiments for estimating enzyme and pharmacokinetic experiments
23. Some suggestions for measuring predictive performance
24. Evaluation of methods for estimating population pharmacokinetic parameters II: Biexponential model and experimental pharmacokinetic data
25. Underrepresentation of patients 65 years of age or older in cancer-treatment trials